Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
J Clin Endocrinol Metab 103(6):22912301
It's what happens after they start taking it
The index event for the control group was defined as the first-time patients were eligible for inclusion of the study, based on diagnosis of MASLD/MASH, and no use of GLP-1 agonists after their diagnosis
Cardiovascular outcomes trials have demonstrated reduced rates of major adverse cardiovascular events in high-risk patients treated with liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial)
Drugs 70 (4), 489512
US$ 22.01
US$ 21.26
US$ 28.24
US$ 27.50
US$ 29.92
